Business Context and Reporting Period
This Form 8-K Current Report was filed by Bausch Health Companies Inc. on December 12, 2025. The filing details a significant debt refinancing event involving Bausch + Lomb Corporation, a subsidiary of the Company.
Key Financial Metrics and Transaction Details
The report focuses on a debt restructuring rather than operational financial performance metrics such as revenue or profit.
- New Debt Issuance: $2,802,125,000 in new term B loans ("Replacement Term Loans").
- Debt Refinanced: Proceeds will refinance outstanding Term B loans due 2031 ("Third Amendment Term Loans") and Term B loans due 2028 ("First Incremental Term Loans").
- Interest Rate Margins:
- 3.75% per annum for loans based on term SOFR.
- 2.75% per annum for loans based on the alternate base rate.
- Maturity Date: January 15, 2031.
Material Changes Versus Prior Period
The refinancing results in the following material changes to the Company's debt structure:
- Interest Cost Reduction: The new margin represents a 0.50% per annum reduction compared to the Third Amendment Term Loans and a 0.25% per annum reduction compared to the First Incremental Term Loans.
- Maturity Extension: The maturity of the First Incremental Term Loans is extended from September 29, 2028, to January 15, 2031.
- Debt Consolidation: Two separate tranches of debt are being consolidated into a single tranche with a uniform maturity date.
Outlook, Risks, and Contingencies
Closing Timeline: The transactions are anticipated to close in the first quarter of 2026.
Risks and Contingencies: The filing explicitly states that there can be no assurances that Bausch + Lomb will be able to complete the transactions on the terms described or at all. The financial benefits, including interest rate reductions and maturity extensions, are contingent upon the successful closing of the deal.
Key Facts for Investor Verification
- Verify the actual closing of the $2.8 billion refinancing in Q1 2026.
- Confirm the final interest rate margins and any potential changes from the anticipated 3.75% (SOFR) and 2.75% (Base Rate).
- Monitor for any prepayment penalties or fees associated with retiring the 2028 and 2031 debt tranches.
- Assess the impact of the extended maturity date on the Company's long-term liquidity profile.